| Filed On | Filing |
|---|---|
| 16 Nov 2026 | 144 |
| 13 Nov 2026 | 144 |
| 13 Nov 2026 |
8-K: Other Events
Incyte Corporation (the “Company”) has decided not to proceed with the planned Phase 3 MAESTRA-3 study evaluating INCB123667, the Company’s selective CDK2 inhibitor, in combination with bevacizumab as first-line maintenance therapy in pa... |
| 12 Nov 2026 | SCHEDULE 13G/A |
| 10 Nov 2026 |
Form 4: Stein Steven H, CMO & Head of Late-Stage Dev.
Received 240,193 shares by exercise or conversion ($19.5M) · Sold 240,193 shares ($28.4M) |
| 06 Nov 2026 | 144 |
| 05 Nov 2026 |
Form 4: Tray Thomas, Principal Accounting Officer
Sold 610 shares ($72.6K) |
| 03 Nov 2026 | 144 |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
Total revenue of $1.56 billion and total net sales of $1.32 billion in the third quarter of 2026, each an increase of 14% compared to the third quarter of 2025 |
| 19 Oct 2026 |
Form 4: Cagnoni Pablo J, President, Global Head of R&D
Received 2,642 shares by exercise or conversion ($174K) · Sold 2,642 shares ($298K) |
| 15 Oct 2026 | 144 |
| 05 Oct 2026 |
Form 4: Heeson Lee, EVP, Head of Incyte Intl
Gave up 463 shares to cover exercise price or tax ($54.2K) |
| 02 Oct 2026 |
Form 4: Baker Bros. Advisors Lp, Director and 5 others
Received 644 shares as a grant or award |
| 02 Oct 2026 |
Form 4: Clancy Paul J, Director
Received 203 shares as a grant or award ($24.6K) |
| 02 Oct 2026 |
Form 4: Harrigan Edmund, Director
Received 206 shares as a grant or award ($25K) |
| 24 Sep 2026 |
Form 4: Gardner David H, EVP, Chief Strategy Officer
Gave up 920 shares to cover exercise price or tax ($117K) |
| 17 Sep 2026 |
Form 4: Cagnoni Pablo J, President, Global Head of R&D
Received 23,218 shares by exercise or conversion ($1.54M) · Sold 23,218 shares ($2.8M) |
| 15 Sep 2026 | 144 |
| 31 Aug 2026 |
8-K: Other Events
Incyte Corporation (the “Company”) today announced that it has entered into an agreement with the U.S. Centers for Medicare & Medicaid Services (“CMS”) intended to improve access to medicines for American patients while supporting contin... |
Loading...